LGI1-antibody Patients Follow-up (evoLGI1)

Civil Hospices of Lyon

Status: Unknown

Conditions: Anti-LGI1 Encephalitis

Study type: Observational

Funder types: Other

Identifiers

NCT04106765

evoLGI1

Details and patient eligibility

About

Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders.

This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.

Enrollment: 192 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.
• Clinical follow-up in France

Exclusion criteria

• Anti-LGI1 antibody associated with another encephalitis antibody
• Foreign follow-up

Trial design

192 participants in 2 patient groups

: epileptic LGI1-antibody patients

Description:

Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom Evaluated items: * Number of seizures * Type of seizures * Presence of EEG abnormalities * Presence of IRM abnormalities * Time before cognitive disorders

cognitive LGI1-antibody patients

Description:

Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom Evaluated items: * Presence of EEG abnormalities * Presence of IRM abnormalities * Time before epileptic seizures